Levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding

被引:24
作者
Hurskainen, R [1 ]
Paavonen, J [1 ]
机构
[1] Helsinki Univ Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland
关键词
hysterectomy; levonorgestrel-releasing intrauterine system; menorrhagia; heavy menstrual bleeding; health benefits;
D O I
10.1097/00001703-200412000-00009
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose of review Menorrhagia is a frequent reason for women to seek medical care and an increasingly common health problem. The levonorgestrel-releasing intrauterine system is an effective medical treatment for menorrhagia. Emerging clinical and research evidence suggests that this new treatment modality has major health benefits. Recent findings The levonorgestrel-releasing intrauterine system is a cost-effective treatment modality for menorrhagia. The quality of life improves significantly which is comparable to that gained with hysterectomy. The costs are about half those of hysterectomy after 5 years of follow-up. Unscheduled breakthrough bleeding is the most common side effect of the treatment. There are different new theories about the mechanism underlying this problem. Women with endometriosis or fibroids also benefit from this treatment. Summary Because menorrhagia is often a reason for seeking medical attention, it is important to consider the outcomes and costs to provide the most appropriate care. The levonorgestrel-releasing intrauterine system improves health-related quality of life significantly at relatively low cost. It is the most effective medical treatment for menorrhagia and comparable to surgical interventions. The system is not associated with serious complications. Although not all women are successfully treated, about 60% avoid hysterectomy and are satisfied with the treatment. Thus, the levonorgestrel-releasing intrauterine system should be the first line of treatment for heavy menstrual bleeding.
引用
收藏
页码:487 / 490
页数:4
相关论文
共 30 条
[1]  
[Anonymous], 2000, COCHRANE DATABASE SY
[2]  
[Anonymous], COCHRANE DATABASE SY, DOI [10.1002/14651858.CD003855, DOI 10.1002/14651858.CD003855]
[3]  
[Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001776.PUB2
[4]   Local levonorgestrel regulation of androgen receptor and 17β-hydroxysteroid dehydrogenase type 2 expression in human endometrium [J].
Burton, KA ;
Henderson, TA ;
Hillier, SG ;
Mason, JI ;
Habib, F ;
Brenner, RM ;
Critchley, HOD .
HUMAN REPRODUCTION, 2003, 18 (12) :2610-2617
[5]   Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding [J].
Crosignani, PG ;
Vercellini, P ;
Mosconi, P ;
Oldani, S ;
Cortesi, I ;
DeGiorgi, O .
OBSTETRICS AND GYNECOLOGY, 1997, 90 (02) :257-263
[6]   Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient [J].
Fong, YF ;
Singh, K .
CONTRACEPTION, 1999, 60 (01) :51-53
[7]   Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas [J].
Grigorieva, V ;
Chen-Mok, M ;
Tarasova, M ;
Mikhailov, A .
FERTILITY AND STERILITY, 2003, 79 (05) :1194-1198
[8]   A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia -: effect on FSH levels and menopausal symptoms [J].
Halmesmäki, K ;
Hurskainen, R ;
Tiitinen, A ;
Teperi, J ;
Grenman, S ;
Kivelä, A ;
Kujansuu, E ;
Yliskoski, M .
HUMAN REPRODUCTION, 2004, 19 (02) :378-382
[9]   Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use [J].
Hickey, M ;
Dwarte, D ;
Fraser, IS .
HUMAN REPRODUCTION, 1998, 13 (11) :3190-3196
[10]   Surface vascularization and endometrial appearance in women with menorrhagia or using levonorgestrel contraceptive implants. Implications for the mechanisms of breakthrough bleeding [J].
Hickey, M ;
Fraser, IS .
HUMAN REPRODUCTION, 2002, 17 (09) :2428-2434